PortfoliosLab logo
Harrow Health, Inc. (HROW)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US4158581094

CUSIP

415858109

IPO Date

Sep 28, 2007

Highlights

Market Cap

$895.12M

EPS (TTM)

-$0.49

Total Revenue (TTM)

$212.86M

Gross Profit (TTM)

$158.64M

EBITDA (TTM)

$24.97M

Year Range

$11.39 - $59.23

Target Price

$57.44

Short %

15.01%

Short Ratio

5.05

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart


Loading data...

Returns By Period

Harrow Health, Inc. (HROW) returned -27.27% year-to-date (YTD) and 110.34% over the past 12 months. Over the past 10 years, HROW delivered an annualized return of 11.89%, outperforming the S&P 500 benchmark at 10.46%.


HROW

YTD

-27.27%

1M

3.92%

6M

-53.53%

1Y

110.34%

5Y*

41.21%

10Y*

11.89%

^GSPC (Benchmark)

YTD

-3.77%

1M

7.44%

6M

-5.60%

1Y

8.37%

5Y*

14.12%

10Y*

10.46%

*Annualized

Monthly Returns

The table below presents the monthly returns of HROW, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025-8.44%-8.59%-5.27%-6.88%-1.49%-27.27%
2024-14.91%13.64%22.16%-22.98%76.15%16.38%23.41%56.94%11.12%0.22%-6.99%-19.95%199.55%
20231.76%19.31%18.08%19.23%-25.25%0.95%15.97%-31.30%-5.27%-0.21%-35.63%21.34%-24.12%
2022-13.19%2.80%-11.54%-0.73%6.79%0.69%-7.69%33.78%34.26%-0.33%-7.32%32.38%70.83%
202131.20%-14.78%-11.99%13.63%19.95%0.98%-3.98%18.83%-14.25%11.00%-0.89%-13.60%25.95%
2020-25.19%-5.15%-30.80%17.54%20.49%-3.70%5.18%25.73%-18.87%-14.85%20.80%19.30%-11.83%
20194.75%16.44%-28.24%-6.43%30.26%43.33%-10.92%-30.97%5.05%-11.03%25.00%24.48%36.73%
201810.00%-2.67%-3.30%29.55%-2.19%-1.35%6.82%29.36%-8.55%53.60%10.77%20.30%234.71%
2017-10.40%8.93%70.90%-2.40%-23.34%2.56%-19.38%-29.07%-12.02%-6.83%14.00%-0.58%-32.00%
2016-14.00%-31.54%-2.70%-0.50%-1.27%-3.59%2.93%7.75%-8.63%-29.40%1.12%-8.09%-63.92%
2015-1.73%1.76%6.53%1.00%5.33%-4.35%-3.20%-2.16%-16.62%21.34%-13.61%2.97%-7.60%
2014147.32%4.09%-22.43%5.07%-20.57%23.93%5.91%6.12%-4.87%15.90%-1.74%-11.24%123.21%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

With an overall rank of 89, HROW is among the top 11% of stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of HROW is 8989
Overall Rank
The Sharpe Ratio Rank of HROW is 9292
Sharpe Ratio Rank
The Sortino Ratio Rank of HROW is 9393
Sortino Ratio Rank
The Omega Ratio Rank of HROW is 9090
Omega Ratio Rank
The Calmar Ratio Rank of HROW is 8888
Calmar Ratio Rank
The Martin Ratio Rank of HROW is 8282
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Harrow Health, Inc. (HROW) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

Harrow Health, Inc. Sharpe ratios as of May 11, 2025 (values are recalculated daily):

  • 1-Year: 1.56
  • 5-Year: 0.56
  • 10-Year: 0.17
  • All Time: -0.06

These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns (including price changes and dividends).

The chart below shows the rolling Sharpe ratio of Harrow Health, Inc. compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time. For deeper analysis or to customize the calculation, use the Sharpe ratio tool.


Loading data...

Dividends

Dividend History


Harrow Health, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading data...

Worst Drawdowns

The table below displays the maximum drawdowns of the Harrow Health, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Harrow Health, Inc. was 99.46%, occurring on Mar 19, 2012. The portfolio has not yet recovered.

The current Harrow Health, Inc. drawdown is 82.32%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.46%Oct 11, 20071118Mar 19, 2012

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading data...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Harrow Health, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of Harrow Health, Inc., comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -90.0%.


-0.40-0.200.000.200.4020212022202320242025
-0.38
-0.20
Actual
Estimate

Valuation

The Valuation section provides an overview of how Harrow Health, Inc. is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for HROW relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, HROW has a P/S ratio of 4.5. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for HROW in comparison with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, HROW has a P/B value of 12.4. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items